GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CF PharmTech 2652.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

5.04

-2.33%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥432.5m

FY2022FY2025

Net income

CN¥2.5m

FY2022FY2025

Free cash flow

−CN¥261.4m

FY2022FY2025

Shareholders' equity

CN¥1.47bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
RevenueCN¥432.5mCN¥607.8mCN¥556.4mCN¥349.1m
Gross profitCN¥327.9mCN¥491.4mCN¥457.5mCN¥267.5m
Research and developmentCN¥124.5mCN¥307.5mCN¥302.4mCN¥203.1m
Operating income−CN¥6.9mCN¥21.0mCN¥22.7m−CN¥70.5m
Net incomeCN¥2.5mCN¥21.1mCN¥31.7m−CN¥49.4m
Diluted earnings per share0.010.060.09-0.14

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assetsCN¥1.78bnCN¥1.26bnCN¥1.14bnCN¥1.02bn
Cash and short-term investments—CN¥348.0mCN¥401.5mCN¥420.9m
Total liabilitiesCN¥307.9mCN¥319.7mCN¥225.1mCN¥153.3m
DebtCN¥97.8mCN¥58.2mCN¥19.2mCN¥240,000
Shareholders' equityCN¥1.47bnCN¥939.3mCN¥910.0mCN¥861.9m
Shares outstanding412m363m363m363m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−CN¥110.3mCN¥96.5mCN¥116.3mCN¥45.5m
Capital spending−CN¥151.1m−CN¥200.6m−CN¥138.3m−CN¥120.6m
Free cash flow−CN¥261.4m−CN¥104.2m−CN¥22.0m−CN¥75.1m

Latest quarters

By quarter end

Jun 2025Mar 2025Dec 2024Mar 2024
RevenueCN¥69.9mCN¥135.9mCN¥607.8mCN¥139.8m
Gross profitCN¥48.6mCN¥107.9mCN¥491.4mCN¥115.1m
Operating income−CN¥19.6mCN¥12.0mCN¥21.0mCN¥5.7m
Net income−CN¥14.0mCN¥12.8mCN¥21.1mCN¥6.2m
Diluted earnings per share-0.030.030.060.02
Cash from operations−CN¥52.0m−CN¥6.0mCN¥96.0m−CN¥10.0m
Capital spending−CN¥28.0m−CN¥30.0m−CN¥200.0m−CN¥37.0m
Free cash flow−CN¥80.0m−CN¥36.0m−CN¥104.0m−CN¥47.0m
Total assets—CN¥1.25bn——
Cash and short-term investments—CN¥305.9m——
Debt—CN¥66.2m——
Shareholders' equity—CN¥958.7m——

Financial ratios

Data as of 7 Oct 2026

FY2025FY2024FY2023FY2022
Gross margin75.8%80.9%82.2%76.6%
Operating margin-2.5%3.4%4.1%-20.2%
Net margin0.6%3.5%5.7%-14.1%
Return on equity0.2%2.2%3.5%-5.7%
Return on assets0.1%1.7%2.8%-4.9%
Free cash flow yield1.5%———
Revenue growth-28.8%9.2%59.4%—
Earnings growth-88.2%-33.5%-164.2%—
Current ratio4.59x1.88x2.89x3.53x
Debt to equity0.07x0.06x0.02x0.00x
Equity ratio82.7%74.6%80.2%84.9%
Interest coverage-4.28x2.33x1.71x-5.15x
R&D as a share of sales28.8%50.6%54.3%58.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.8%——
Operating income-53.9%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin78.8%79.4%——

Valuation history

At each fiscal year end

FY2025
Price to sales29.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.